HOPX and acute myeloid leukemia: They found that the signatures of eight monocytes/macrophages, including HOPX, were related to shorter survival time and predicted drug sensitivity to the PARP inhibitor ABT-888 and the tyrosine kinase inhibitor Axitinib in patients with AML.